ASACOL

This brand name is authorized in Australia, Canada, Cyprus, Germany, Estonia, Spain, Finland, Hong Kong, Israel, Italy, Japan, Lithuania, Malta, Mexico, Netherlands, New Zealand, Singapore, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug ASACOL contains one active pharmaceutical ingredient (API):

1 Mesalazine UNII 4Q81I59GXC - MESALAMINE

Mesalazine is an aminosalicylate. The mechanism of action of mesalazine is not fully understood, but appears to have a topical anti-inflammatory effect on the colonic epithelial cells. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase and lipoxygenase pathways, is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalazine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon. Read about Mesalazine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A07EC02	Mesalazine	A Alimentary tract and metabolism → A07 Antidiarrheals, intestinal antiinflammatory/antiinfective agents → A07E Intestinal antiinflammatory agents → A07EC Aminosalicylic acid and similar agents
Discover more medicines within A07EC02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 11210B, 12463Y
Country: CA	Health Products and Food Branch	Identifier(s): 02267217
Country: DE	Bundesinstitut für Arzneimittel und Medizinprodukte	Identifier(s): 06343853, 06344255, 11223186, 11223200, 15619030, 15619047, 17259015, 17259021
Country: EE	Ravimiamet	Identifier(s): 1146541, 1146574, 1155743, 1184969, 1184970
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 57726, 78448
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 008429, 062812, 151589, 156636, 184234, 431473, 434718
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 175332, 301770, 301774, 301777, 381175, 381176
Country: HK	Department of Health Drug Office	Identifier(s): 27305, 51118, 51119
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 1288, 4910
Country: IT	Agenzia del Farmaco	Identifier(s): 026416139, 026416141, 026416154, 026416216, 026416230, 026416255, 026416305, 026416317, 026416329
Country: JP	医薬品医療機器総合機構	Identifier(s): 2399009F3028
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1004332, 1004333, 1004551, 1016722, 1021778
Country: MT	Medicines Authority	Identifier(s): AA565/00803, AA565/00804, AA565/00805, AA565/00806
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 025M97
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 24538, 44954
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 15422, 5393, 5394
Country: SG	Health Sciences Authority	Identifier(s): 03021P, 14275P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699586042058, 8699586043369, 8699586892035, 8699586912047
Country: US	FDA, National Drug Code	Identifier(s): 0023-5901
Country: ZA	Health Products Regulatory Authority	Identifier(s): 37/11.1/0629, S/11.10/171, Z/11.10/205, Z/11.10/206